NOVA EYE MEDICAL LIMITED Financials Nova Eye Medical Limited
Equities
EYE
AU0000094252
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.275 AUD | +1.85% |
|
+10.00% | +14.58% |
| Mar. 15 | Nova Eye Medical Completes Retail Entitlement Offer | MT |
| Feb. 22 | Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: June | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 76.11 | 26.93 | 50.44 | 62.92 | - | - |
| Enterprise Value (EV) 1 | 75.82 | 20.88 | 43.02 | 55.92 | 58.52 | 57.72 |
| P/E ratio | -13.2 x | -3.57 x | -2.7 x | -6.29 x | -22.2 x | 275 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.93 x | 2.01 x | 2.96 x | 2.86 x | 2.05 x | 1.63 x |
| EV / Revenue | 0.93 x | 1.56 x | 2.53 x | 2.54 x | 1.91 x | 1.5 x |
| EV / EBITDA | -73.8 x | -3.28 x | -4.95 x | -8.22 x | 97.5 x | 11.2 x |
| EV / FCF | -15.4 x | -3.11 x | -5.64 x | -6.66 x | -27.9 x | 48.1 x |
| FCF Yield | -6.51% | -32.2% | -17.7% | -15% | -3.59% | 2.08% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 143,601 | 145,580 | 190,328 | 228,797 | - | - |
| Reference price 2 | 0.5300 | 0.1850 | 0.2650 | 0.2750 | 0.2750 | 0.2750 |
| Announcement Date | 8/28/19 | 8/26/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Giugno | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 81.64 | - | - | 13.38 | 17.02 | 22 | 30.7 | 38.5 |
| EBITDA 1 | -1.027 | - | - | -6.371 | -8.692 | -6.8 | 0.6 | 5.15 |
| EBIT 1 | -5.038 | - | - | -8.182 | -10.99 | -9.1 | -1.45 | 3.1 |
| Operating Margin | -6.17% | - | - | -61.16% | -64.55% | -41.36% | -4.72% | 8.05% |
| Earnings before Tax (EBT) 1 | -5.656 | - | - | -8.246 | -17 | -9.1 | -1.45 | 3.1 |
| Net income 1 | -5.773 | 35.65 | -4.356 | -7.496 | -15.29 | -8.6 | -1.2 | 3.05 |
| Net margin | -7.07% | - | - | -56.03% | -89.83% | -39.09% | -3.91% | 7.92% |
| EPS 2 | -0.0402 | - | - | -0.0518 | -0.0981 | -0.0437 | -0.0124 | 0.001000 |
| Free Cash Flow 1 | -4.933 | - | - | -6.721 | -7.624 | -8.4 | -2.1 | 1.2 |
| FCF margin | -6.04% | - | - | -50.24% | -44.78% | -38.18% | -6.84% | 3.12% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 23.3% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 39.34% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/28/19 | 8/28/20 | 8/18/21 | 8/26/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2024 S1 |
|---|---|---|
| Net sales 1 | 41.8 | 10.14 |
| EBITDA 1 | -0.1 | -4.184 |
| EBIT | -2.803 | - |
| Operating Margin | -6.71% | - |
| Earnings before Tax (EBT) | -2.933 | - |
| Net income 1 | -2.7 | -5.625 |
| Net margin | -6.46% | -55.48% |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 2/20/20 | 2/22/24 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 0.29 | - | - | 6.06 | 7.42 | 7 | 4.4 | 5.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -4.93 | - | - | -6.72 | -7.62 | -8.4 | -2.1 | 1.2 |
| ROE (net income / shareholders' equity) | -8.13% | - | - | -22.8% | -57.1% | -39.5% | -11.8% | 1% |
| ROA (Net income/ Total Assets) | -5.68% | - | - | -19.1% | -45.7% | -33.4% | 2.5% | 21.1% |
| Assets 1 | 101.7 | - | - | 39.31 | 33.49 | 25.75 | -48 | 14.45 |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | - | - | -0.0200 | 0.0100 | 0.0300 |
| Capex 1 | 0.73 | - | - | 0.13 | 0.26 | 1.2 | 1 | 1 |
| Capex / Sales | 0.89% | - | - | 1% | 1.54% | 5.45% | 3.26% | 2.6% |
| Announcement Date | 8/28/19 | 8/28/20 | 8/18/21 | 8/26/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.275
AUD
Average target price
0.5
AUD
Spread / Average Target
+81.82%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.58% | 41.03M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- EYE Stock
- Financials Nova Eye Medical Limited
